Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)
Close on Nov 17, 2026Market cap $10.88MP/E –Yield –
Bolt Biotherapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Bolt Biotherapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$24.80M. For fiscal 2025 it was -$39.85M. The highest annual figure on record is -$39.85M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$39.85M | – |
| FY2024 | Dec 31, 2024 | -$61.29M | – |
| FY2023 | Dec 31, 2023 | -$69.53M | – |
| FY2022 | Dec 31, 2022 | -$76.50M | – |
| FY2021 | Dec 31, 2021 | -$57.07M | – |
| FY2020 | Dec 31, 2020 | -$47.31M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$3.08M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.02M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.16M | – |
| Q3 FY2025 | Sep 30, 2025 | -$9.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$14.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.27M | – |
| Q3 FY2023 | Sep 30, 2023 | -$16.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -$15.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.40M | – |
| Q4 FY2022 | Dec 31, 2022 | -$17.95M | – |
| Q3 FY2022 | Sep 30, 2022 | -$13.45M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.31M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.73M | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.99M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$12.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.52M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$9.64M | – |
See a number that looks wrong?